


## EXPRESS MAIL MAILING LABEL

No. EL953996882 USPATENT  
Attorney Docket No.: MEE-005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Adamis *et al.*  
SERIAL NO.: 09/478,099 GROUP NO.: 1632  
FILING DATE: January 5, 2000 EXAMINER: Baker, A.  
TITLE: Targeted Transscleral Controlled Release Drug Delivery to the Retina  
and Choroid

Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☒ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☒ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

### STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:


- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Date: November 20, 2002  
Reg. No.: 38,678

Tel. No.: (617) 248-7317  
Fax No.: (617) 248-7100

2506593\_1

Respectfully submitted,

  
\_\_\_\_\_  
Duncan A. Greenhalgh  
Attorney for Applicants  
Testa, Hurwitz, & Thibeault, LLP  
High Street Tower  
125 High Street  
Boston, Massachusetts 02110



EXAM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MEE-005

APPLICANTS: Adamis *et al.*

SERIAL NO.: 09/478,099


FILING DATE: January 5, 2000 GROUP: 1632

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A1	3,618,604	11/9/71	Ness et al.	128	260	
	A2	3,692,027	9/19/72	Ellinwood, Jr.	128	260	
	A3	3,961,628	6/8/76	Arnold	128	260	
	A4	3,963,025	6/15/76	Whitaker et al.	128	260	
	A5	4,003,379	1/18/77	Ellinwood, Jr.	128	260	
	A6	4,014,335	3/29/77	Arnold	128	260	
	A7	4,146,029	3/27/79	Ellinwood, Jr.	128	260	
	A8	4,177,256	12/4/79	Michaels et al.	424	22	
	A9	4,180,073	12/25/79	Michaels	128	260	
	A10	4,186,184	1/29/80	Zaffaroni	424	14	
	A11	4,203,442	5/20/80	Michaels	128	260	
	A12	4,281,654	8/4/81	Shell et al.	128	260	
	A13	4,360,019	11/23/82	Portner et al.	128	213 R	
	A14	4,475,916	10/9/84	Himmelstein	604	890	
	A15	4,544,371	10/1/85	Dormandy, Jr. et al.	604	891	
	A16	4,734,092	3/29/88	Millerd	604	67	
	A17	4,957,494	9/18/90	Wong et al.	604	892.1	
	A18	4,959,217	9/25/90	Sanders et al.	424	473	
	A19	5,061,242	10/29/91	Sampson	604	118	
	A20	5,236,689	8/17/93	Wong et al.	424	473	
	A21	5,266,332	11/30/93	Dong et al.	424	473	
	A22	5,300,114	4/5/94	Gwon et al.	623	4	
EXAMINER				DATE CONSIDERED			



<b>FORM PTO - 1449</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTORNEY DOCKET NO.: MEE-005</b>  <b>APPLICANTS:</b> Adamis <i>et al.</i>  <b>SERIAL NO.:</b> 09/478,099  <b>FILING DATE:</b> January 5, 2000 <b>GROUP:</b> 1632			
<b>U.S. PATENT DOCUMENTS</b>							
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	A23	5,348,746	9/20/94	Dong et al.	424	473	
	A24	5,366,454	11/22/94	Currie et al.	604	890.1	
	A25	5,378,475	1/3/95	Smith et al.	424	473	
	A26	5,391,381	2/21/95	Wong et al.	424	473	
	A27	5,443,508	8/22/95	Giampapa	623	11	
	A28	5,445,616	8/29/95	Kratoska et al.	604	141	
	A29	5,466,233	11/14/95	Weiner et al.	604	890.1	
	A30	5,475,096	12/12/95	Gold et al.	536	23.1	
	A31	5,582,981	12/10/96	Toole et al.	435	6	
	A32	5,607,418	3/4/97	Arzbaeher	604	891.1	
	A33	5,660,846	8/26/97	Cheikh	424	423	
	A34	5,725,493	3/10/98	Avery et al.	604	9	
	A35	5,736,152	4/7/98	Dunn	424	426	
	A36	5,756,291	5/26/98	Griffin et al.	435	6	
	A37	5,773,019	6/30/98	Ashton et al.	424	423	
	A38	5,797,898	8/25/98	Santini, Jr. et al.	604	890.1	
	A39	5,830,173	11/3/98	Avery et al.	604	9	
	A40	5,840,867	11/24/98	Toole et al.	536	23.1	
	A41	5,869,078	2/9/99	Baudino	424	423	
	A42	5,888,533	3/30/99	Dunn	424	423	
	A43	5,897,878	4/27/99	Dong et al.	424	473	
	A44	5,902,598	5/11/99	Chen et al.	424	423	
	A45	5,993,414	11/30/99	Haller	604	93	
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			



<b>FORM PTO - 1449</b>				<b>ATTORNEY DOCKET NO.: MEE-005</b>			
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>				<b>APPLICANTS:</b> Adamis <i>et al.</i>			
				<b>SERIAL NO.:</b> 09/478,099			
				<b>FILING DATE:</b> January 5, 2000 <b>GROUP:</b> 1632			
<b>U.S. PATENT DOCUMENTS</b>							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A46	6,001,386	12/14/99	Ashton et al.	424	423	
	A47	6,056,734	5/2/00	Jacobsen et al.	604	891.1	
	A48	6,074,673	6/13/00	Guillen	424	501	
	A49	6,120,789	9/19/00	Dunn	424	426	
	A50	6,123,861	9/26/00	Santini, Jr. et al.	216	2	
	A51	6,165,155	12/26/00	Jacobsen et al.	604	156	
	A52	6,203,523 B1	3/20/01	Haller et al.	604	93.01	
	A53	6,217,896 B1	4/17/01	Benjamin	424	427	
	A54	6,251,090 B1	6/26/01	Avery et al.	604	9	
	A55	6,277,401 B1	8/21/01	Bello et al.	424	449	
	A56	6,283,949 B1	9/4/01	Roorda	604	288.02	
	A57	6,283,951 B1	9/4/01	Flaherty et al.	604	529	
	A58	6,306,420 B1	10/23/01	Cheikh	424	422	
	A59	6,312,393 B1	11/6/01	Abreu	600	558	
	A60	6,317,630 B1	11/13/01	Gross et al.	604	20	
	A61	6,319,245 B1	11/20/01	Berrigan	604	891.1	
	A62	6,331,313 B1	12/18/01	Wong et al.	424	427	
	A63	6,364,865 B1	4/2/02	Lavi et al.	604	411	
	A64	6,368,626 B1	4/9/02	Bhatt et al.	424	473	
	A65	6,368,629 B1	4/9/02	Watanabe et al.	424	482	
	A66	6,375,972 B1	4/23/02	Guo et al.	424	423	
	A67	2002/0026176 A1	2/28/02	Varner et al.	604	891.1	
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			



<b>FORM PTO - 1449</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTORNEY DOCKET NO.: MEE-005</b>  <b>APPLICANTS:</b> Adamis <i>et al.</i>  <b>SERIAL NO.:</b> 09/478,099  <b>FILING DATE:</b> January 5, 2000 <b>GROUP:</b> 1632				
<b>U.S. PATENT DOCUMENTS</b>								
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	A68	6,413,540 B1	7/2/02	Yaacobi	424	427		
	A69	6,416,777 B1	7/9/02	Yaacobi	424	428		
<b>FOREIGN PATENT DOCUMENTS</b>								
EXAM. INIT.	DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B1	86/00519 A	1/30/86	WO				Y
	B2	91/16869	11/14/91	WO				Y
	B3	93/21874	11/11/93	WO				Y
	B4	94/05257	3/17/94	WO				Y
	B5	94/13305	6/23/94	WO				Y
	B6	94/21314 A	9/29/94	WO				Y
	B7	00/38714	7/6/00	WO				Y
	B8	00/40089 A	7/13/00	WO				Y
	B9	01/28472 A1	4/26/01	WO				Y
	B10	01/28474 A1	4/26/01	WO				Y
	B11	01/30323	5/3/01	WO				Y
	B12	01/80825 A	11/1/01	WO				Y
<b>OTHER ART, JOURNAL ARTICLES, ETC.</b>								
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)							
	C1	Ambati, J. <i>et al.</i> "Diffusion of High Molecular Weight Compounds Through Sclera" <u>Invest. Ophthalmol. Vis. Sci.</u> (2000) 41: 1181-1185.						
	C2	Canakis <i>et al.</i> "Characterization of Diffusion Across the Sclera Using FITC-Conjugates of Different Molecular Weights" <u>Invest. Ophthalmol. Vis. Sci.</u> (1997) Abstract 38: 683-B594.						
EXAMINER				DATE CONSIDERED				



FORM 11-1449		ATTORNEY DOCKET NO.: MEE-005	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANTS: Adamis <i>et al.</i>	
		SERIAL NO.: 09/478,099	
		FILING DATE: January 5, 2000 GROUP: 1632	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C3	Carrasquillo <i>et al.</i> "Controlled Delivery of Anti-VEGF Aptamer EYE001 with Poly(lactic-co-glycolic) Acid Microspheres" Poster presentation in 2002.	
	C4	The Eyetech Study Group "Preclinical and Phase 1A Clinical Evaluation of an Anti-VEGF Pegylated Aptamer (EYE001) for the Treatment of Exudative Age-Related Macular Degeneration" <u>J. Retinal Vitreous Diseases</u> (2002) 22: 143-152	
	C5	Jellinek <i>et al.</i> "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor" <u>Biochem.</u> (1994) 33: 10450-10456	
	C6	Jo, B. <i>et al.</i> "Fabrication of Three-Dimensional Microfluidic Systems by Stacking Molded Polydimethylsiloxane (PDMS) Layers" <u>SPIE</u> (1999) 3877: 222-229.	
	C7	Ruckman <i>et al.</i> "2'-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF <sub>165</sub> )" <u>J. Biol. Chem.</u> (1998) 273: 20556-20567.	
	C8	Santini, J. Jr. <i>et al.</i> "A Controlled-release Microchip" <u>Nature</u> (1999) 397: 335-338.	
EXAMINER		DATE CONSIDERED	